The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The Peptide Moment: How FDA's Regulatory Reversal Creates Risk and Opportunity for Venture Capital and Private Equity Guidepost Solutions Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law Regulatory Alert: The Legal Status of BPC 157 in Compounding and Clinical Practice Holt Law Best BPC 157 Oral Supplements: ProHealth's Triple Tested Formula Examined as Peptide Quality Verification Becomes Consumer Priority Heading Into 2026 Intrado RFK Jr.'s peptide push could unleash risky drugs STAT First Opinion